IF 2.3

Breathe Pub Date : 2024-07-16 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.5028-2023

引用次数: 0

Unravelling the diagnostic pathology and molecular biomarkers in lung cancer. 揭示肺癌的病理诊断和分子生物标记物。

IF 2.3

Breathe Pub Date : 2024-07-16 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0192-2023

Andriani Charpidou, Georgia Hardavella, Efimia Boutsikou, Emmanouil Panagiotou, Gökçen Ömeroğlu Simsek, Koen Verbeke, Daniela Xhemalaj, Joanna Domagała-Kulawik

{"title":"Unravelling the diagnostic pathology and molecular biomarkers in lung cancer.","authors":"Andriani Charpidou, Georgia Hardavella, Efimia Boutsikou, Emmanouil Panagiotou, Gökçen Ömeroğlu Simsek, Koen Verbeke, Daniela Xhemalaj, Joanna Domagała-Kulawik","doi":"10.1183/20734735.0192-2023","DOIUrl":"10.1183/20734735.0192-2023","url":null,"abstract":"The progress in lung cancer treatment is closely interlinked with the progress in diagnostic methods. There are four steps before commencing lung cancer treatment: estimation of the patient's performance status, assessment of disease stage (tumour, node, metastasis), recognition of histological subtype, and detection of biomarkers. The resection rate in lung cancer is <30% and >70% of patients need systemic therapy, which is individually adjusted. Accurate histological diagnosis is very important and it is the basis of further molecular diagnosis. In many cases only small biopsy samples are available and the rules for their assessment are defined in this review. The use of immunochemistry with at least thyroid transcription factor 1 (TTF1) and p40 is decisive in distinction between lung adenocarcinoma and squamous cell carcinoma. Molecular diagnosis and detection of known driver mutations is necessary for introducing targeted therapy and use of multiplex gene panel assays using next-generation sequencing is recommended. Immunotherapy with checkpoint inhibitors is the second promising method of systemic therapy with best results in tumours with high programmed death-ligand 1 (PD-L1) expression on cancer cells. Finally, the determination of a full tumour pattern will be possible using artificial intelligence in the near future.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"230192"},"PeriodicalIF":2.3,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A 46-year-old woman presenting with anterior mediastinal mass and superior vena cava obstruction syndrome. 一名 46 岁女性，出现前纵隔肿块和上腔静脉阻塞综合征。

IF 2.3

Breathe Pub Date : 2024-07-16 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0038-2024

Soumi Chakraborty, Suranjan Mukherjee, Arighna Mukherjee, Mithun Chaudhuri

引用次数: 0

Contemporary management of mesothelioma. 间皮瘤的当代管理。

IF 2.3

Breathe Pub Date : 2024-07-16 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0175-2023

Mark D J Neilly, Jennifer Pearson, Akari Win Thu, Carolyn MacRae, Kevin G Blyth

{"title":"Contemporary management of mesothelioma.","authors":"Mark D J Neilly, Jennifer Pearson, Akari Win Thu, Carolyn MacRae, Kevin G Blyth","doi":"10.1183/20734735.0175-2023","DOIUrl":"10.1183/20734735.0175-2023","url":null,"abstract":"Pleural mesothelioma (PM) is an aggressive asbestos-associated thoracic malignancy with a median survival of 12-18 months. Due to continued asbestos use in many nations, global incidence is rising. Causes due to non-occupational, environmental exposure are also rising in many countries despite utilisation bans. For many years, platinum--pemetrexed chemotherapy was the solitary licensed therapy, but first-line combination immune checkpoint blockade has recently demonstrated improved outcomes, with both regimes tested in predominantly late-stage cohorts. In the second-line setting, single-agent nivolumab has been shown to extend survival and is now available for routine use in some regions, while second-line chemotherapy has no proven role and opportunities for clinical trials should be maximised in relapsed disease. Surgery for \"technically resectable\" disease has been offered for decades in many expert centres, but the recent results from the phase III MARS2 trial have challenged this approach. There remains no robustly proven standard of care for early-stage PM. The clinical trial landscape for PM is complex and increasingly diverse, making further development of specialist PM multidisciplinary teams an important priority in all countries. The observation of improving outcomes in centres that have adopted this service model emphasises the importance of high-quality diagnostics and equitable access to therapies and trials. Novel therapies targeting a range of aberrations are being evaluated; however, a better understanding of the molecular drivers and their associated vulnerabilities is required to identify and prioritise treatment targets.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"230175"},"PeriodicalIF":2.3,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pleural effusion in a patient with previous alcohol excess. 一名酗酒患者的胸腔积液。

IF 2.3

Breathe Pub Date : 2024-07-16 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0036-2024

Richard Eddery, Lucy Searle, Mubashar Iqbal, Victoria Athey

引用次数: 0

Increasing exercise capacity and physical activity in the COPD patient. 增强慢性阻塞性肺病患者的运动能力和体育锻炼。

IF 2

Breathe Pub Date : 2024-06-11 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0347-2023

Antarpreet Kaur, Jean Bourbeau, Lisa Brighton, Bartolome Celli, Rebecca Crouch, Heleen Demeyer, Daniel A Gerardi, Hideki Katsura, Paula Meek, Mike Morgan, Mara Paneroni, Sally Singh, Michael K Stickland

{"title":"Increasing exercise capacity and physical activity in the COPD patient.","authors":"Antarpreet Kaur, Jean Bourbeau, Lisa Brighton, Bartolome Celli, Rebecca Crouch, Heleen Demeyer, Daniel A Gerardi, Hideki Katsura, Paula Meek, Mike Morgan, Mara Paneroni, Sally Singh, Michael K Stickland","doi":"10.1183/20734735.0347-2023","DOIUrl":"10.1183/20734735.0347-2023","url":null,"abstract":"Higher levels of exercise capacity and physical activity are desired outcomes in the comprehensive management of the COPD patient. In addition, improvements in exercise capacity and physical activity are instrumental to optimising other important therapeutic goals, such as improved health status, reduced healthcare utilisation and increased survival. Four general approaches towards increasing exercise capacity and physical activity in individuals with COPD will be discussed in this review: 1) pharmacological intervention, especially the administration of long-acting bronchodilators; 2) pulmonary rehabilitation, including exercise training and collaborative self-management; 3) behavioural interventions; and 4) web-based interventions. These are by no means the only approaches, nor are they mutually exclusive: indeed, combining them, as necessary, to meet the needs of the individual respiratory patient may promote optimal outcomes, although further research is necessary in this area.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"230347"},"PeriodicalIF":2.0,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11167654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unravelling the complex interplay of factors behind exercise limitations and physical inactivity in COPD. 揭示慢性阻塞性肺病患者运动受限和缺乏运动背后复杂的相互作用因素。

IF 2

Breathe Pub Date : 2024-06-11 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0180-2023

Clarice Y Tang, Bruce Bernstein, Felicity Blackstock, Astrid Blondeel, Andrea Gershon, Elena Gimeno-Santos, Rainer Gloeckl, Alda Marques, Martijn A Spruit, Chris Garvey, Mike Morgan, Linda Nici, Sally J Singh, Thierry Troosters

引用次数: 0

Prevalence and prognostic importance of exercise limitation and physical inactivity in COPD. 慢性阻塞性肺病患者运动受限和缺乏运动对预后的重要性。

IF 2

Breathe Pub Date : 2024-06-11 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0179-2023

Anouk W Vaes, Chris Burtin, Richard Casaburi, Bartolome R Celli, Rachael A Evans, Suzanne C Lareau, Linda Nici, Carolyn L Rochester, Thierry Troosters

{"title":"Prevalence and prognostic importance of exercise limitation and physical inactivity in COPD.","authors":"Anouk W Vaes, Chris Burtin, Richard Casaburi, Bartolome R Celli, Rachael A Evans, Suzanne C Lareau, Linda Nici, Carolyn L Rochester, Thierry Troosters","doi":"10.1183/20734735.0179-2023","DOIUrl":"10.1183/20734735.0179-2023","url":null,"abstract":"Exercise limitation and physical inactivity are separate, but related constructs. Both are commonly present in individuals with COPD, contribute to disease burden over and above the respiratory impairments, and are independently predictive of adverse outcomes. Because of this, clinicians should consider assessing these variables in their patients with COPD. Field tests of exercise performance such as the 6-min walk test and the incremental and endurance shuttle walk tests require limited additional resources, and results correlate with negative outcomes. Laboratory measures of exercise performance using a treadmill or cycle ergometer assess exercise capacity, provide prognostic information and have the advantage of explaining physiological mechanisms (and their interactions) underpinning exercise limitation. Limitations in exercise capacity (i.e. \"cannot do\") and physical inactivity (i.e. \"do not do\") are both associated with mortality; exercise limitation appears to be the more important driver of this outcome.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 2","pages":"230179"},"PeriodicalIF":2.0,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11167648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of medical thoracoscopy in managing pleural malignancy. 使用内科胸腔镜治疗胸膜恶性肿瘤。

IF 2

Breathe Pub Date : 2024-06-11 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0174-2023

Avinash Aujayeb, Philippe Astoul

引用次数: 0

The importance of addressing physical activity and exercise intolerance in our patients with COPD. 解决慢性阻塞性肺病患者的体育锻炼和运动不耐受问题的重要性。

IF 2

Breathe Pub Date : 2024-06-11 eCollection Date: 2024-06-01 DOI: 10.1183/20734735.0272-2023

Roger Goldstein, José R Jardim, Linda Nici, Jonathan Raskin, Martijn A Spruit, Richard ZuWallack

引用次数: 0

Breathe最新文献